Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at :

NCT ID NCT01896479
Title A Study of Two Different Doses of Cabozantinib (XL184) in Progressive, Metastatic Medullary Thyroid Cancer
Recruitment Active, not recruiting
Gender both
Phase FDA approved
Variant Requirements Yes
Sponsors Exelixis

thyroid gland medullary carcinoma



Age Groups: senior | adult
Covered Countries ITA | FRA | ESP | CAN

Additional content available in CKB BOOST